167 related articles for article (PubMed ID: 37964682)
41. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
42. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
[TBL] [Abstract][Full Text] [Related]
43. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer.
Quintana Á; Peg V; Prat A; Moliné T; Villacampa G; Paré L; Galván P; Dientsmann R; Schmid P; Curigliano G; Muñoz-Couselo E; Perez-García J; Marti M; Blanco-Heredia J; Anjos CD; Vazquez M; De Mattos-Arruda L; Cortés J
Eur J Cancer; 2021 May; 148():134-145. PubMed ID: 33743482
[TBL] [Abstract][Full Text] [Related]
44. Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.
Huang M; A Fasching P; Haiderali A; Xue W; Yang C; Pan W; Zhou ZY; Hu P; Chaudhuri M; Le Bailly De Tilleghem C; Cappoen N; O'Shaughnessy J
Adv Ther; 2023 Mar; 40(3):1153-1170. PubMed ID: 36648737
[TBL] [Abstract][Full Text] [Related]
45. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
46. TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.
Dadiani M; Necula D; Kahana-Edwin S; Oren N; Baram T; Marin I; Morzaev-Sulzbach D; Pavlovski A; Balint-Lahat N; Anafi L; Wiemann S; Korner C; Gal-Yam EN; Avivi C; Kaufman B; Barshack I; Ben-Baruch A
Cancer Immunol Immunother; 2020 Jul; 69(7):1315-1326. PubMed ID: 32198536
[TBL] [Abstract][Full Text] [Related]
47. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
48. Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.
Yan J; Li C; Zhang X; Cheng L; Ding R; Zhang L
Front Public Health; 2022; 10():942800. PubMed ID: 35923949
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
[No Abstract] [Full Text] [Related]
50. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer.
Phua LC; Lee SC; Ng K; Abdul Aziz MI
BMC Health Serv Res; 2020 Jun; 20(1):581. PubMed ID: 32580722
[TBL] [Abstract][Full Text] [Related]
51. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
[No Abstract] [Full Text] [Related]
52. First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
Weng X; Huang X; Li H; Lin S; Rao X; Guo X; Huang P
Am J Clin Oncol; 2020 May; 43(5):340-348. PubMed ID: 32028340
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer.
Huang Y; Huang X; Huang X; Lin S; Luo S; Gu D; Weng X; Xu X
Hum Reprod; 2023 Jun; 38(6):1099-1110. PubMed ID: 37075316
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of a population-based AAA screening program for men over 65 years old in Iran.
Daroudi R; Shafe O; Moosavi J; Salimi J; Bayazidi Y; Zafarghandi MR; Maleki M; Moini M; Farshidmehr P; Sadeghipour P
Cost Eff Resour Alloc; 2021 May; 19(1):29. PubMed ID: 33985531
[TBL] [Abstract][Full Text] [Related]
55. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
56. Predictive and Prognostic Value of Tumor- Infiltrating Lymphocytes for Pathological Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
Mohammed AA; Mostafa Elsayed F; Algazar M; Rashed HE
Gulf J Oncolog; 2022 Jan; 1(38):53-60. PubMed ID: 35156645
[TBL] [Abstract][Full Text] [Related]
57. Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis.
Li S; Zhang Y; Zhang P; Xue S; Chen Y; Sun L; Yang R
Breast; 2022 Dec; 66():97-109. PubMed ID: 36219945
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.
Chisaki Y; Kuwada Y; Matsumura C; Yano Y
Clin Drug Investig; 2021 Apr; 41(4):381-389. PubMed ID: 33674955
[TBL] [Abstract][Full Text] [Related]
60. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]